Molecular determinants of P2Y 2 receptor desensitization and sequestration have been investigated. Wildtype P2Y 2 receptors and a series of five C-terminal truncation mutants of the receptor were epitope-tagged and stably expressed in 1321N1 cells. These constructs were used to assess the importance of the intracellular C terminus on 1) UTP-stimulated increases in intracellular calcium concentration, 2) homologous desensitization of the receptor, and 3) agonist-induced decreases in cellsurface density (receptor sequestration) of epitopetagged receptors using fluorescence-activated cell sorting. The potency and efficacy of UTP were similar for the wild-type and all mutant P2Y 2 receptors. Truncation of 18 or more amino acids from the C terminus increased by ϳ30-fold the concentration of UTP necessary to desensitize the receptor. Both the rate and magnitude of UTP-induced receptor sequestration were decreased with progressively larger truncations of the C terminus. Furthermore, the recovery from sequestration was slower for the most extensively truncated receptor. Complete desensitization was obtained with >50% of the original receptor complement remaining on the cell surface. Protein kinase C activation, which desensitizes the P2Y 2 receptor, had no effect on sequestration, consistent with the ideas that desensitization and sequestration are discrete events and that agonist occupancy is required for receptor sequestration.Responses to extracellular nucleotides are mediated by P2 receptors that belong to two receptor superfamilies: P2Y G protein-coupled receptors (GPCRs) 1 and P2X ligand-gated ion channels. Multiple P2Y subtypes have been classified pharmacologically and molecularly and are predominantly linked to activation of phospholipase C and increased levels of inositol 1,4,5-trisphosphate and diacylglycerol, leading to elevations in the intracellular free calcium concentration ([Ca 2ϩ ] i ) and the activation of protein kinase C (PKC) (1-4). The P2Y 2 nucleotide receptor subtype (formerly the P 2U receptor) is distinguished pharmacologically from the other known mammalian P2Y receptor subtypes by the equal potency and efficacy of the naturally occurring agonists ATP and UTP.Activation of P2Y 2 receptors present in airway epithelium increases Cl Ϫ secretion through Ca 2ϩ -dependent and outwardly rectifying Cl Ϫ channels (5). It has been shown that P2Y 2 receptor activation by UTP in airway epithelia of cystic fibrosis patients can increase Cl Ϫ secretion, thereby effectively bypassing the defective cAMP-dependent Cl Ϫ transport (6). Like other members of the GPCR superfamily, P2Y 2 receptors undergo agonist-induced desensitization (7), but little is known about the mechanisms involved in desensitization of the P2Y 2 receptor. It seems likely that a fuller understanding of desensitization and the signaling pathways that affect the P2Y 2 receptor may lead to improved therapies targeted to this receptor.Desensitization of GPCRs is a complex process involving phosphorylation of the receptors by multiple pro...